Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

ENDRA Life Sciences Inc. Warrants NDRAW NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score
46/100
2/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

ENDRA Life Sciences Inc. Warrants (NDRAW) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $0.03. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Net income is $7M (loss), growing at +16.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $492,352 against $2M equity (Debt-to-Equity (D/E) ratio 0.22, conservative). Current ratio is 1.29 (adequate). Debt-to-assets is 12.8%. Total assets: $4M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 80/100 (Pass), Past 0/100 (Fail), Health 75/100 (Pass), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

NDRAW SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 80/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NDRAW

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
80/100
NDRAW: +0%/yr revenue is, +16.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet NDRAW: Debt-to-Equity (D/E) ratio 0.22 (conservative), Current ratio is 1.29 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
NDRAW: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.01-0.03
Volume113.76K
Beta (1Y)4.23
Share Statistics
EPS (TTM)-8.93
Shares Outstanding$787.02K
IPO Date2017-06-28
CEONone
Financial Highlights & Ratios
EBITDA$-5.61M
Net Income$-7.03M
Operating Income$-5.76M
Total Cash$762.37K
Total Debt$492.35K
Net Debt$-270.01K
Total Assets$3.85M
Price / Earnings (P/E)-0
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD

Price Chart

Track all markets on TradingView
NDRAW
ENDRA Life Sciences Inc. Warrants  ·  NASDAQ Capital Marke
Healthcare • Medical - Diagnostics & Research
0.01 52WK RANGE 0.03

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message